

## CADTH REIMBURSEMENT REVIEW

# Stakeholder Feedback on Draft Recommendation

**abrocitinib (Cibingo)**  
(Pfizer Canada ULC.)

**Indication:** Atopic dermatitis, moderate to severe

**August 5, 2022**

**Disclaimer:** The views expressed in this submission are those of the submitting organization or individual. As such, they are independent of CADTH and do not necessarily represent or reflect the view of CADTH. No endorsement by CADTH is intended or should be inferred.

By filing with CADTH, the submitting organization or individual agrees to the full disclosure of the information. CADTH does not edit the content of the submissions.

CADTH does use reasonable care to prevent disclosure of personal information in posted material; however, it is ultimately the submitter's responsibility to ensure no identifying personal information or personal health information is included in the submission. The name of the submitting stakeholder group and all conflicts of interest information from individuals who contributed to the content are included in the posted submission.

# CADTH Reimbursement Review

## Feedback on Draft Recommendation

Stakeholder information	
CADTH project number	SR0686
Name of the drug and Indication(s)	Abrocitinib (Cibinqo) for the treatment of patients 12 years and older with refractory moderate to severe atopic dermatitis, including the relief of pruritus, who have had an inadequate response to other systemic drugs (e.g. steroid or biologic), or for whom these treatments are not advisable. Abrocitinib can be used with or without medicated topical therapies for atopic dermatitis
Organization Providing Feedback	FWG

### 1. Recommendation revisions

Please indicate if the stakeholder requires the expert review committee to reconsider or clarify its recommendation.

Request for Reconsideration	Major revisions: A change in recommendation <b>category</b> or patient <b>population</b> is requested	<input type="checkbox"/>
	Minor revisions: A change in reimbursement <b>conditions</b> is requested	<input type="checkbox"/>
No Request for Reconsideration	Editorial revisions: Clarifications in recommendation <b>text</b> are requested	<input type="checkbox"/>
	No requested revisions	X

### 2. Change in recommendation category or conditions

Complete this section if major or minor revisions are requested

Please identify the specific text from the recommendation and provide a rationale for requesting a change in recommendation.

### 3. Clarity of the recommendation

Complete this section if editorial revisions are requested for the following elements

#### a) Recommendation rationale

Please provide details regarding the information that requires clarification.

#### b) Reimbursement conditions and related reasons

Please provide details regarding the information that requires clarification.

#### c) Implementation guidance

Please provide high-level details regarding the information that requires clarification. You can provide specific comments in the draft recommendation found in the next section. Additional implementation questions can be raised here.